News
PLRX
1.210
-1.63%
-0.020
Pliant Therapeutics to present PLN-101095 trial data at ASCO meeting
PUBT · 23h ago
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Barchart · 1d ago
Weekly Report: what happened at PLRX last week (0511-0515)?
Weekly Report · 4d ago
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)
TipRanks · 05/13 04:55
Analyst Reiterates Hold on Pliant Therapeutics, Keeps 12-Month Price Target Unchanged at $3 Amid Early-Stage Risk-Reward Balance
TipRanks · 05/12 12:25
Piper Sandler Remains a Buy on Pliant Therapeutics (PLRX)
TipRanks · 05/12 11:36
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ligand Pharma (LGND), Pliant Therapeutics (PLRX) and Oculis Holding (OCS)
TipRanks · 05/12 11:21
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SI-Bone (SIBN), Pliant Therapeutics (PLRX) and Steris (STE)
TipRanks · 05/12 11:11
Pliant Therapeutics Q1 net loss narrows on lower expenses
Reuters · 05/11 21:10
Pliant Therapeutics reports Q1 EPS (32c), consensus (36c)
TipRanks · 05/11 20:57
Press Release: Pliant Therapeutics Provides -2-
Dow Jones · 05/11 20:05
*Pliant Therapeutics 1Q Loss/Shr 32c >PLRX
Dow Jones · 05/11 20:05
*Pliant Therapeutics 1Q Loss $20M >PLRX
Dow Jones · 05/11 20:05
Weekly Report: what happened at PLRX last week (0504-0508)?
Weekly Report · 05/11 10:18
Pliant Therapeutics joins RBC Capital Markets Global Healthcare Conference fireside chat
PUBT · 05/06 12:33
Weekly Report: what happened at PLRX last week (0427-0501)?
Weekly Report · 05/04 10:16
Pliant Therapeutics doses first participant in FORTIFY expansion trial
TipRanks · 04/30 13:41
Pliant doses first patient in Phase 1b FORTIFY trial of PLN-101095 combo therapy
PUBT · 04/30 12:39
Pliant Therapeutics Announces Dosing Of First Participant In FORTIFY Phase 1b Open-Label Indication Expansion Clinical Trial Of PLN-101095 In Combination With Pembrolizumab, In Patients With ICI-Refractory Advanced Or Metastatic Solid Tumors
Benzinga · 04/30 12:33
PLIANT THERAPEUTICS INC - ENROLLMENT IS UNDERWAY WITH INTERIM DATA EXPECTED IN 2027
Reuters · 04/30 12:30
More
Webull provides a variety of real-time PLRX stock news. You can receive the latest news about Pliant Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.